The local medical community is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in scientific trials for addressing obesity. This https://tvsocialnews.com/story7408085/retatrutide-australia-australia-a-new-hope-for-weight-loss